Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia

WEN DU1*, YANJIE HU1*, CONG LU1, JUAN LI1, WEI LIU1, YANLI HE1, PING WANG1, CHEN CHENG2, YU HU3, SHIANG HUANG1 JUNXIA YAO1 and JIN'E ZHENG1

1Center for Stem Cell Research and Application, 2Tumor Center, 3Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China

Received December 15, 2014; Accepted February 25, 2015

DOI: 10.3892/mco.2015.552

Abstract. Resistance to chemotherapy is a major challenge for leukemia treatment. It has been suggested that leukemia stem cells (LSCs), a small pool of self-renewing leukemic cells, play important roles in development of chemotherapy resistance. The expression of cluster of differentiation 96 (CD96), a potential marker for LSCs, was investigated in CD34+CD38- cells of 105 acute leukemia (AL) patients by flow cytometry. The data showed that all the CD34+, CD34+CD38+ and CD34+CD38-CD96+ proportions were much higher in AL compared to the normal control (P<0.01), while a clear difference was identified in the CD34+CD38- and CD34+CD38-CD96+ proportions between acute lymphoid leukemia and acute myeloid leukemia (AML). However, all the AML patients with >15% CD34+CD38+ cells achieved complete remission (CR), suggesting that as an LSC-rich population, the amount of CD34+CD38+ cells may not be positively associated with the proportion of refractory LSCs. The mean percentage of the co-presence of CD96 expression itself was similar in AML patients with CR and non-CR (P>0.05). However, the CR rate was significantly higher in the AML population with <10% CD96 expressed, which indicated that a distinct sub-group of CD34+CD38-CD96+ cells may still contribute to the drug resistance or poor prognosis.

Introduction

According to the cancer stem cell model, the small pool of self-renewing cancer stem cells must be eliminated in order to eradicate the tumor (1-4). Acute myeloid leukemia (AML) is a developmental disease characterized by clonal growth and subsequent accumulation of myeloid blasts in the bone marrow (BM), which is initiated and maintained by a subset of self-renewing leukemia stem cells (LSCs). Thus far, human AML stem cells are the most extensively characterized cancer stem cell population. LSCs share numerous properties with hematopoietic stem cells (HSC) with the ability of self-renewal. Thus, it has been suggested that the clonal progression of preleukemia may occur in a succession of HSC subclones until augmented or poorly regulated self-renewal pathways are activated, leading to the emergence of final stage LSCs usually at the level of a downstream progenitor (5).

A number of studies have shown that LSC-enriched populations are resistant to various chemotherapy agents and are therefore possibly responsible for the outgrowth of minimal residual disease, which in turn is believed to cause relapse (6,7). Thus, the expression profile of LSCs specific cell surface markers may be used as a prognosis factor to predict the drug response in AML patients. Similar to the normal HSCs, AML-LSC are enriched in the CD34+CD38+ population (8). However, AML-LSCs also express certain unique cell surface marker combinations, such as CD123+CD117+, CD90+, CD47+ and intermediate aldehyde dehydrogenase activity (9-13). CD96 (T cell-activated increased late expression) is a transmembrane glycoprotein possessing three extracellular immunoglobulin-like domains (14), which is expressed by T and NK cells but not the majority of B cells, monocytes and granulocytes in human peripheral blood cells (15). Notably however, CD96 has been identified as an LSC-specific marker in human AML (16,17). Although, the functions and prognosis value of CD96 expression in human AML remains unclear.

The present study investigated the potential co-association between CD96 expression and chemotherapy response in AML, acute lymphoid leukemia (ALL) and mixed lineage acute leukemia (MAL) patients, to increase the understanding of the role of CD96 in leukemia diagnosis and prognosis.

Materials and methods

Patient samples. BM samples of 105 acute leukemia (AL) patients presenting with AML, ALL and MAL at the Union...
Hospital Center for Stem Cell Research and Application (Wuhan, China) were obtained following informed consent at diagnosis and following chemotherapeutic treatment. A total of 15 normal BM samples were collected as control. The mean age was 48 years and ranged from 2 month to 82 years. The study was approved by the Research Ethics Committee at the Union Hospital. Patient distributions are shown in Table I. Diagnosis and identification of subtypes for the patients was based on morphology using the French-American-British classification, immune-phenotyping, molecular genetics and cytogenetics, and fluorescence in situ hybridization (18). All the AML patients were induced by a dose-adjusted regimen, except AML-M3. The complete remission (CR) group was defined as first CR. When the patient could not achieve the first CR within two induction treatments, or relapsed in 6 months after the first CR, they were classified into the non-CR (NCR) group.

Flow cytometry. The majority of the samples were analyzed freshly. Red blood cells (RBCs) were lysed using a 10 min lysing procedure on ice with 10 ml lysis buffer [155 mmol/l NH4Cl, 10 mmol/l KHCO3, 0.1 mmol/l Na2 and ethylenediaminetetraacetic acid (pH 7.4)] and washed with phosphate-buffered agar (PBA) [phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin]. The monoclonal antibodies (10 µl; BD Biosciences, Franklin Lakes, NJ, USA) CD38 fluorescein isothiocyanate, CD34 phycoerythrin and CD96 were added respectively to a certain volume of whole BM according to the cell counts (~5x106 cells/tube). Subsequently the samples were maintained in the dark at 4°C for 30 min. The samples were lysed with fluorescence-activated cell sorting (FACS) lysing solution (BD Biosciences) for 10 min, followed by washing with PBA once at ~1,000 x g at 4°C for 5 min. Finally, the cell pellets were resuspended in 300 µl PBS and the data was collected by FACS Calibur™ (BD Biosciences).

Statistical analysis. The data were analyzed using the SPSS software package (version 16.0 for Windows; SPSS, Inc., Chicago, IL, USA) in the study. All the variables were presented as mean values and standard error (SE) or median and interquartile range with the independent samples group t-test or χ2 test. Analysis of the prognosis was performed using the Wilcoxon signed ranks. All the statistical tests were two-sided and P<0.05 was considered to indicate a statistically significant difference.

Results

CD34/CD38/CD96 expression in AL patients. The frequencies of CD34+, CD34+CD38- and CD34+CD38-CD96+ populations were analyzed in BM nucleated cells from a cohort of 105 AL and 15 healthy volunteers. The information of the patients and healthy volunteers as normal controls is summarized in the Table I. A total of 20,000 nucleated cells were analyzed for each specimen to evaluate the expression of CD34 and 2,000 gated-CD34+ cells were collected when analyzing with CD38 and CD96.

As expected, the frequency of the CD34+ population in nucleated cells was low (<4.6%) in all the healthy volunteers with the mean of 2.07%. However, its expression varied significantly in AL patients, with the mean value of 35.20% (median 30.26%, SE 0.72%), which was much higher in comparison to the normal controls (P<0.01). Similarly, as shown in Figs. 1 and 2, the proportion of the CD34+CD38- population in nucleated cells was <0.6% (mean 0.10%, median 0.03%, SE 0.01%) in all the healthy volunteers, which was 9.22% (median 2.36%, SE 0.14%) in AL patients, indicating the significant difference between them (P<0.01). Subsequently, the CD96 expression in CD34+CD38- cells was examined. As shown in Figs. 1 and 3, the CD34+CD38- cells from healthy volunteers had less expression of CD96, with the mean of 7.78% (median 4.00%, SE 0.99%), while the proportion was as high as 29.36% (median 7.32%, SE 0.40%) in the 105 AL patients. The difference had clear significance (P<0.01).

The CD34 expression also varied significantly in AML patients, with the mean value of 35.12% (median 27.80%, SE 0.32%), which was significantly higher compared to the healthy controls (P<0.01), but was close to the total AL samples. Similarly, the proportion of the CD34+CD38- population in nucleated cells in healthy volunteers was much lower compared to the AML patients (P<0.01), which was at the mean of 6.91% (median 1.25%, SE 0.15%). In addition, CD96 expression on CD34+CD38- cells in AML patients (mean 26.71%, median 5.57%, SE 0.33%) was also significantly higher compared to the normal control (P<0.01).

The CD34 expression in ALL patients was at the mean value of 39.15% (median 35.20%, SE 2.33%), which was significantly higher compared to the healthy controls (P<0.01), but there was no difference when comparing with the AML patients (P>0.05). The CD34+CD38- cells in the ALL patients was at the mean value of 24.48% (median 23.22%, SE 1.44%), which was significantly higher compared to the healthy controls (P<0.01), but still much lower than the AML patients (P<0.01). The CD96 expression in the CD34+CD38- cells in the ALL patients (mean 11.34%, median 0.74%, SE 1.86%) was higher compared to the normal controls (P<0.01).
was similar to the normal controls (P>0.05) and lower than the AML patients (P<0.05). With regards to MAL, further analysis or comparisons were not performed due to the limited cases.

**CD34/CD38/CD96 expression in the AML subtypes.** The differences between 3 subtypes of AML (M1, M2, and M4) were considered, which had ≥10 samples in each group. Only the CD34 expression in M2 and M4 patients had a statistical difference (P<0.05). None of the other indices, including CD34+ cell percentages in the M1 and M2 or M1 and M4 groups, CD34+CD38- proportions and CD96 expression in the 3 subtypes, were identified as significantly different (P>0.05).

**Association of CD34+CD38- and CD96+ expression with the chemotherapy response in AML patients.** The presence of LSCs has been proposed to be an important reason for drug
These patients were divided into two groups according to the frequencies of the CD34+/CD38− population in nucleated cells. The results showed that in 17 NCR patients, the CD34+/CD38− proportion was at the mean of 2.31% (median 0.23%, SE 0.28%), which was different from that in 38 CR patients with the mean of 8.19% (median 1.97%, SE 0.34%) (P<0.05). However, further data suggested that all 10 cases of AML patients with >15% CD34+/CD38− cells achieved CR, while 17 out of 45 patients (38%) who had <15% CD34+/CD38− cells remained NCR (P<0.01), as shown in Fig. 4 and Table II. Therefore, all the 17 NCR patients had <15% CD34+/CD38− cells in nucleated cells.

Subsequently, whether CD96 expression in the CD34+/CD38− cells was correlated with drug resistance in AML patients was examined. The results showed there was no difference in the CD96+ proportion between the 17 NCR patients at the mean of 30.09% and 38 CR patients at the mean of 22.09% (P>0.05). Of note, 65% NCR patients had >10% CD34+/CD38− CD96+ population in the CD34+/CD38− cells, while only 32% CR patients had the same level of CD34+/CD38− CD96+ population (P<0.01). Therefore, 11 out of 23 patients (48%) with >10% CD96 expression remained NCR, while the rate in patients with <10% CD96 cells was only 19% (P<0.01). The results are shown in Fig. 4 and Table III.

Discussion

CD96 had previously been reported to express on T and NK cells, but not on B cells, granulocytes, monocytes or RBCs (17,19). However, recent studies suggested that CD96 was a putative marker expressed by LSCs in AML patients. Although the physiological functions of CD96 on AML-LSCs are unknown, it may contribute to their adhesion to the BM compartment. To increase the understanding of the association of CD96 expression and CD34+/CD38− stem cell markers and subsequently to reveal the role of CD96 in leukemia, the CD34+/CD38−CD96+ expression and the clinical characteristics in 105 AL patients, including 87 AML, 15 ALL and 3 MAL, and 15 healthy volunteers as normal controls were examined.

As expected, the frequency of the CD34+ population in nucleated cells was much lower than that in the AL patients (P<0.01), which was in the same situation as CD34+/CD38− and CD34−CD38− CD96+ expression (P<0.01), as shown in Figs. 1-3. Advanced analysis also showed that AML and ALL had higher CD34+ and CD34+CD38− cells compared to the normal controls (P<0.01). These results were consistent with previous studies (13,20,21). However, the present data also showed that although there were high frequencies and no difference in CD34+ expression between AML and ALL (P>0.05), the CD34+CD38− cells in ALL patients was significantly lower than that in the AML patients (P<0.01). In addition, there were still evident differences of CD96 expression on CD34+CD38− cells in ALL patients with that in AML; the former was similar to the normal controls (P>0.05) and lower than the AML patients (P<0.05). The results suggested that, regardless of the several studies indicating a population of LSC exhibiting a CD34+CD38− phenotype in ALL and AML (22,23), the proportions were different. CD96 may not appear to be a potential distinguished LSCs marker in ALL. However, except for the statistical difference of CD34

![Figure 4. Mean of CD34+CD38− and CD96+ proportions in newly diagnosed AML patients who achieved CR or NCR.](Image)
expression in the M2 and M4 patients (P<0.05), none of the other indices, including the CD34+ cell percentages in the M1 and M2 or M1 and M4 groups, CD34+CD38+ proportions and CD96 expression in the 3 subtypes of AML (M1, M2 and M4), were identified as different (P>0.05). Sufficient cases may be studied to evaluate the diversity.

Numerous studies were performed to reveal the characteristics and function of leukemia stem cells. One of the most prevalent aims focused on the CD34+CD38- LSC-enriched cells, which had been proposed as an important factor in drug resistance. Certain studies described that the fraction of CD34+CD38- cells at the time of diagnosis exhibited a significant correlation with poor prognosis in childhood ALL of B-cell lineage and AML (20,21). Of note, the present results showed that in 17 NCR patients out of 55 AML cases, the mean of CD34+CD38- proportion in CD34+ cells at the new diagnosis time was lower compared to the 38 CR AML patients (P<0.05). Furthermore, all 10 cases of AML patients with >15% CD34+CD38- cells achieved CR, while 17 out of 45 patients (38%) who had <15% CD34+CD38- cells remained NCR (P<0.01), as shown in Fig. 4 and Table II. In summary, all 17 NCR patients had <15% CD34+CD38- cells in nucleated cells. However, conflicting results were not identified between our and the previous study. The previous studies analyzed the fraction of CD34+CD38- cells based on total abnormal cells, which may or may not include a significant number of CD34- cells. The CD34+CD38- cells were counted based on pure CD34+ cells, which varied significantly in all the AL patients even in a similar proportion of abnormal cells, but may be more comparable. This type of percentage was selected as it may avoid the inaccuracy of too few CD34+CD38- cells for the rare CD34+ cells, and waive the difference resulting from the unbalance of various amounts of CD34- cells in the abnormal cells. The frequencies should not simply be compared. The CD34+CD38- proportion in the CD34- cells could also provide a significant explanation for the prognosis of AL. In addition, the results verified that only the CD34+CD38- cells were an enriched marker of LSCs. The amount of LSCs may not be positively correlated with the CD34+CD38- proportion in CD34+ cells, or conversely, lower CD34+CD38- frequencies (<15%) in CD34+ cells may suggest more non-developed LSCs. These results indicated that AML-LSC could be distinguished from normal HSC by the presence of CD96 expression. This finding suggested that CD96 may be an excellent candidate target for antibody therapy against LSC. The therapy may be developed by the CD96 antibodies that induce cytotoxicity, such as antibody-dependent cell-mediated cytotoxicity, augmented macrophage phagocytosis or complement dependent cytotoxicity (24). Further research should focus on identifying the real LSCs.

Subsequently, the mean CD96+ proportion between 17 NCR patients and 38 CR patients was compared and there was no difference (P>0.05). Notably, as shown in Fig. 4 and Table III, the data showed that 65% of NCR patients had >10% CD34+CD38+CD96+ population in CD34+CD38- cells, while only 32% CR patients had the same level of CD34+CD38+CD96+ population (P<0.01). In summary, 11 out of 23 patients (48%) with >10% CD96 expression remained NCR, while the rate in patients with <10% CD96 cells was only 19% (P<0.01). The results strongly indicated that a higher expression of CD96 (>10%) may promote a poor response for chemotherapy, which may be closely associated with primary resistant. Of note, CD96 was proved to be an efficient identical marker of LSCs in CD34+CD38- groups, which was consistent with previous studies (16,17). For the limit of adherence and follow-up of the patients, only the outcomes in 55 AML patients with completed clinical data were analyzed, however, it may have a certain association with other types or subtypes of leukemia that require further research.

CD96 expression was also evaluated in CD34+CD38- cells in 14 high-risk MDS BM samples. Although CD96 expression was much higher compared to the normal control, no evidence showed that the CD34+CD38+ or CD34+CD38+CD96+ proportion was associated with MDS chemotherapy efficacy or the prognosis. However, MDS stem cells exhibit a deranged phenotype that is different from normal and AML stem cells, and this may cause them to be particularly difficult to eradicate by therapies targeted against surface antigens.

In conclusion, CD96 was frequently expressed in the CD34+CD38- LSC population in AL patients. CD96 is significantly associated with the response for chemotherapy in AML patients, which strongly suggested that CD96 may be a marker of LSCs, candidate therapeutic target and prediction factor in AL patients.

Acknowledgements

The authors acknowledge the Union Hospital and Center for Stem Cell Research and Application for supporting the research. The present study was supported by the Morning Program, Wuhan Science and Technology Bureau (grant no. 201150431122) and the National Young Scientist's Program of China (grant no. 81100356).

References

1. Rey A, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer and cancer stem cells. Nature 414: 105-111, 2001.
2. Passegué E, Jamieson CH, Ailles LE and Weissman IL: Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reappearance of stem cell characteristics? Proc Natl Acad Sci USA 100 (Suppl 1): 11842-11849, 2003.
3. Warner JK, Wang JCY, Hope KJ, Jin L and Dick JE: Concepts of human leukemic development. Oncogene 23: 7164-7177, 2004.
4. Huntly BJ and Gilliland DG: Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5: 311-321, 2005.
5. Weissman I: Stem cell research: Paths to cancer therapies and regenerative medicine. JAMA 294: 1359-1366, 2005.
6. Costello R, Mallet P, Chambost H, Saintry D, Arnoulet C, Gastaut JA and Olive D: The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): Reduced immunogenecity and high frequency of CD34+/CD38- leukemic progenitors. Leukemia 13: 1513-1518, 1999.
7. van Rhemen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waitsitz Q, Ossenkoppele GJ and Schuurhuis GJ: High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11: 6520-6527, 2005.
8. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
9. Malaise M, Steinbach D and Corbaciglio S: Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep 4: 77-82, 2009.
10. Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K and Inokuchi K: Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 25: 1423-1432, 2011.

11. Park SH, Chi HS, Min SK, Park BG, Jang S and Park CJ: Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 35: 1376-1383, 2011.

12. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL and Majeti R: Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374-1384, 2011.

13. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, et al: A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 119: 3571-3577, 2012.

14. Meyer D, Seth S, Albrecht J, Maier MK, du Pasquier L, Ravens I, Dreyer L, Burger R, Gramatzki M, Schwinzer R, et al: CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains. J Biol Chem 284: 2235-2244, 2009.

15. Fuchs A, Cell M, Giurisato E, Shaw AS and Colonna M: Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 172: 3994-3998, 2004.

16. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, Krensky AM and Weissman IL: CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 104: 11008-11013, 2007.

17. Gramatzki M, Ludwig WD, Burger R, Moos P, Rohwer P, Grünert C, Sendler A, Kalden JR, Andreesen R, Henschke F, et al: Antibodies TC-12 (‘unique’) and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 26: 1209-1214, 1998.

18. Löwenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med 341: 1051-1062, 1999.

19. Wang PL, O’Farrell S, Clayberger C and Krensky AM: Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily. J Immunol 148: 2600-2608, 1992.

20. Ebinger M, Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Lang P and Handgretinger R: High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res 34: 1139-1142, 2010.

21. Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P, Handgretinger R, et al: High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol Oncol 28: 91-99, 2011.

22. Castor A, Nilsson L, Astrand-Grundström I, Buitenhuis M, Ramirez C, Anderson K, Strömbeck B, Garwicz S, Békássy AN, Schmiegelow K, et al: Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11: 630-637, 2005.

23. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, Green J, Colman S, Picciobello W, Buckle V, et al: Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319: 356-359, 2008.

24. Adams GP and Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157, 2005.